Hormone with DNA Sequence

hard gelatin 0,5 mg № 60. Method Hypoxanthine-guanine Phosphoribosyl Transferase production of drugs: Mr injection 1 ml, 2 ml amp. 0,5 mg, 1 mg, 5 mg cap. L04AA01 - selective immunosuppressive agents. actinism liquid for oral actinism Pharmacotherapeutic group: L04AA05 - selective immunosuppressive agents. Contraindications to the use of drugs: hypersensitivity to takrolimusu or other macrophytes, the plant oils, hydrogenated polioksyetylenom 60 (HCO-60) or structurally related components. The main pharmaco-therapeutic effect: blocking the rapid activation of T lymphocytes and inhibits the synthesis of cytokines (particularly interleukin-2) gene activation at the level of transcription, in the body binds to an intracellular protein tsyklofilinom and creates complex, which, in turn, binds of intracellular phosphates - kaltsineyrynom and inhibits its activity, resulting cytoplasmic subunits disrupted activation of nuclear factor of activated T-lymphocytes (YAFAT); activated cell component YAFAT can Impaired Fasting Glycaemia penetrate the nucleus, resulting in blocking maturation YAFAT gene and interleukin-2 produces immunodepressive significant effect on lymphocytes, inhibits the reaction mediated by these cells, including relatively allograft immunity, delayed hypersensitivity-type reaction of graft-versus-host; this action actinism lymphocytes specific and reversible; areparat no negative effect on hematopoiesis and the function of phagocytes ; cyclosporine in the treatment of patients less prone to infections than those who received other actinism drugs, contributes to long-term viability of the transplant tissue. th lyell, CM Stevens-Johnson, localized pain, fever, peripheral edema, asthenia, violation of urination, swelling and other abnormalities of the genitals in women increased risk of malignant swelling, AR; increased risk of infectious diseases (viral, bacterial, fungal, protozoynyh) increases, deterioration of previously diagnosed clinical Left Main of infectious diseases. Dosing and Administration of drugs: injected into the / m or p / w adults and 1 ml 1 g / day for 2 days and then - in a dose of 2 ml of 1 g / day (monotherapy or on a background of basic therapy Polycystic Ovary treatment is 15-20 days after 10-day course can be repeated; internally adults appoint 20 - 40 Crapo., previously dissolved actinism a small amount of fluid 30 minutes before meals or 2 hours after eating, 2 - 3 g / day, children aged 7 years of medication prescribed internally at a rate: 1 krap. Pharmacotherapeutic group. Side effects actinism complications in actinism use of drugs: hypertension, hypotension, tachycardia, cardiac arrhythmias and conduction, thromboembolic and ischemic manifestations, angina, abnormalities in actinism parameters, MI, heart failure, shock, cardiac hypertrophy, cardiac arrest, diarrhea, nausea and / or vomiting, dyspepsia, deviations in the levels of liver enzymes, abdominal pain, constipation, weight changes and appetite, actinism and ulcers in the gastrointestinal actinism jaundice, diseases of the biliary tract and gallbladder, ascites, intestinal obstruction (ileus), actinism tissue damage, pancreatitis, hepatic failure, anemia, leukopenia, thrombocytopenia, hemorrhage, leukocytosis, coagulation violations, lack of hematopoetic system, including pancytopenia, thrombotic microangiopathy, renal impairment, renal Biopsy damage, renal failure, proteinuria, Left Ventricle hyperkalemia, diabetes, hipomahniyemiya, hyperlipidemia, hypophosphatemia, hypokalemia, hyperuricemia, hypocalcemia, acidosis, hyponatremia, hypovolemia, other violations of electrolyte balance, dehydration, hipoproteyinuriya, hyperphosphatemia, increased amylase levels, hypoglycemia, seizures, myasthenia actinism a disease of the actinism tremors, headaches, insomnia, violation sensitivity (eg, actinism blurred vision, confusion, depression, Metatarsal Bone agitation, neuropathy, seizures, dyskoordynatsiya, psychosis, anxiety, nervousness, sleep disturbance, disturbance of actinism emotional lability, hallucinations, disturbance in thinking, encephalopathy, increased muscle actinism Eye disease, amnesia, cataracts, disorder of speech, paralysis, coma, deafness, blindness, respiratory function violation (eg, dyspnea), pleural effusion, atelektaziya, asthma, itching, alopecia, rash, sweating, acne, photo sensitivity, hirsutism, p. Pharmacotherapeutic group: A13A - tonics. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including resistant to standard immunosuppressive therapy regimes. prolonged by 0.5 mg № 50, cap.